This is further supported by results of our analyses of primary, recurrent and non-tumor liver samples from the TCGA Liver cancer (LIHC) cohort (n = 438) which demonstrated that compared to its expression in the non-tumor/normal liver tissues, MALAT1 is significantly expressed in primary and recurrent liver cancer (1-way Anova: p = 2.40 × 10−11, F-value = 25.93) (Supplementary Figure S3). This evidence concerns the gene MALAT1 and liver cancer.